medigraphic.com
Organo Oficial de la Sociedad Mexicana de Urología

2012, Number 5

<< Back Next >>

Rev Mex Urol 2012; 72 (5)

Resultados del manejo de los tumores germinales no seminomatosos en una institución de tercer nivel

González-Cuenca E, Ramírez-Bonilla M, Castillejos-Molina RA, Sotomayor-de Zavaleta M, Feria-Bernal G, Gabilondo-Navarro F, Rodríguez-Covarrubias F

Language: Spanish
References: 19
Page: 220-224
PDF size: 149.40 Kb.


ABSTRACT

Aims: To report the oncologic progression of patients presenting with nonseminomatous germ cell tumors (NSGTs) treated at our institution.
Methods: From 1984-2011, 72 NSGTs were diagnosed. We retrospectively analyzed stage, risk factors, and tumor markers. The evaluated outcomes were overall survival (OS) and recurrence-free survival (RFS).
Results: The most common single histologic strain was embryonal carcinoma. A total of 51% of the cases were low risk, 38% were intermediate risk, and 9% were high risk. The mean follow-up time was 50.48 ± 53.81 months (2-275 month range). Initial treatment was orchiectomy (ORC) and active surveillance (AS) in 23 cases, ORC plus chemotherapy (CT) in 40 cases, and CT followed by ORC in 9 cases. RFS at 10 years was 81% for the low risk patients and 45% for the intermediate risk group; the mean RFS was not reached by the high risk group (p = 0.0006). OS at 10 years was 100% for the low risk group, 79% for the intermediate risk group, and 66% for the high risk group (p ‹ 0.0001).
Conclusions: Nonseminomatous testicular tumor management should be multidisciplinary and based on the international risk group classification.


REFERENCES

  1. Wein AJ, Kavoussi LR, Novick AC, et al. Neoplasm of the Testis (Chapter 29). Campell-Walsh Urology. 9th ed. Philadelphia. Saunders-Elsevier. 2007. 959-992.

  2. Manecksha RP, Fitzpatrick JM. Epidemiology of testicular cancer. BJU Int 2009;104(9 Pt B):1329-1333.

  3. Zheng T, Holford TR, Ma Z, et al. Continuing increase in incidence of germ-cell testis cancer in young adults: experience from Connecticut, USA, 1935-1992. Int J Cancer 1996;65(6):723-729.

  4. Martín FL, Garrido ML, Álvarez EL, et al. Estudio descriptivo de los tumores testiculares germinales: 13 años de experiencia en el área de Badajoz. Arch Esp Urol 2007;60(5):531-537.

  5. Gerson R, Serrano A, Villalobos A. Cáncer testicular: seguimiento a 15 años. Rev Med Hosp Gen Mex 1999;62:16-21.

  6. Juárez DMR, Chavira GC. Epidemiología de los tumores testiculares en derechohabientes del IMSS atendidos en tercer nivel en el Noreste en el periodo 1999-2005. In: Boletín del Colegio Mexicano de Urología. México. El Colegio Mexicano de Urología A.C. 2007. XXII:18-28.

  7. Germa-Lluch JR, García-del Muro X, Maroto P, et al. Clinical pattern and therapeutic results achieved in 1490 patients with germ-cell tumors of the testis: the experience of the Spanish Germ-Cell Cancer Group (GG). Eur Urol 2002;42(6):553-562.

  8. Adami HO, Bergstrom R, Mohner M, et al. Testicular cancer in nine northern European countries. Int J Cancer 1994;59(1):33-38.

  9. Consultado el 01 de octubre de 2012. http://www.dgepi.salud.gob.mx/2010/PDFS/PUBLICACIONES/MONOGRAFIAS/PEPID_TUMORES_MALIGNOS_MEX_2010.pdf.

  10. Consultado el 01 de octubre de 2012. http://www.cancerresearchuk.org/cancer-info/cancerstats/world/the-global-picture/cancer-overall-world.

  11. Huyghe E, Matsuda T, Thonneau P. Increasing incidence of testicular cancer worldwide: a review. J Urol 2003;170(1):5-11.

  12. Scholz M, Holtl W. Stage I testicular cancer. Curr Opin Urol 2003;13(6):473-476.

  13. Edge SB, Byrd DR, Compton CC, et al. AJCC Cancer Staging Manual. 7th ed. New York. Springer. 2010.

  14. International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. International Germ Cell Cancer Collaborative Group. J Clin Oncol 1997;15(2):594-603.

  15. Purdue MP, Devesa SS, Sigurdson AJ, et al. International patterns and trends in testis cancer incidence. Int J Cancer 2005;115(5):822-827.

  16. Foster RS, Donohue JP. Retroperitoneal lymph node dissection for the management of clinical stage I nonseminoma. J Urol 2000;163(6):1788-1792.

  17. Chevreau C, Mazerolles C, Soulie M, et al. Long-term efficacy of two cycles of BEP regimen in high-risk stage I non-seminomatous testicular germ cell tumors with embryonal carcinoma and/or vascular invasion. Eur Urol 2004;46(2):209-214.

  18. Tandstad T, Dahl O, Cohn-Cedermark G, et al. Risk-adapted treatment in clinical stage I non-seminomatous germ cell testicular cancer: the SWENOTECA management program. J Clin Oncol 2009;27(13):2122-2128.

  19. Nicolai N, Miceli R, Necchi A, et al Retroperitoneal lymph node dissection with no adjuvant chemotherapy in clinical stage I non-seminomatous germ cell tumours: long-term outcome and analysis of risk factors of recurrence. Eur Urol 2010;58(6):912-918.




2020     |     www.medigraphic.com